Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
